A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines

Inclusion Criteria : * Toddler in good health based on medical history and medical examination * Toddler aged 12 to 15 months on the day of inclusion * Born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥ 2.5 kg * Provision of informed consent form signed by the parent(s) or other legally acceptable representative (and by an independent witness if required by local regulations) * Participant and parent/delegate able to attend all scheduled visits and comply with all trial procedures * Completion of previous vaccination program according to the national immunization schedule, except for measles Exclusion Criteria : * Family members from the Investigator or from the staff involved in the trial * Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion * Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months) * History of central nervous system disorder or disease, including seizures * History of varicella, measles, mumps, rubella and hepatitis A; confirmed either clinically, serologically, or microbiologically * Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding inclusion * Previous vaccination against measles-mumps-rubella, hepatitis A or varicella * Previous vaccination against flavivirus diseases * Known systemic hypersensitivity to any of the components of the vaccines, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances * Planned participation in another clinical trial during the present trial period * Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the first trial vaccination * Receipt of blood or blood-derived products in the past 3 months, which might interfere with assessment of the immune response * Planned receipt of any vaccine in the 4 weeks following the first trial vaccination * Human immunodeficiency virus (HIV) seropositivity in the blood sample taken at screening * Clinically significant laboratory abnormalities, as judged by the Investigator, in blood sample taken at screening Temporary exclusions: vaccination postponed until the condition is resolved: * Febrile illness (temperature ≥ 38°C) or moderate or severe acute illness/infection on the day of vaccination, according to Investigator judgment * Receipt of oral or injected antibiotic therapy within 72 hours prior to the vaccination visit * Any vaccination received in the 4 weeks preceding vaccination